Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: Role of geranylgeranylation and Rho proteins

Journal of the American Society of Nephrology

Volumn 9, Issue 8, 1998, Pages 1377-1388

  Essig, Marie ^a,b   Vrtovsnik, François ^a,b   Nguyen, Geneviève ^c   Sraer, Jean Daniel ^c   Friedlander, Gérard ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLASMIN; PLASMINOGEN ACTIVATOR; RHO FACTOR;

ANIMAL CELL; ARTICLE; DRUG EFFECT; EXTRACELLULAR MATRIX; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT;

EID: 0031926840     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 318: 1657-1666, 1988
2. MacKensen-Haen S, Bohle A, Christensen J, Wehrmann M, Kendziorra H, Kokot AD: The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases. Clin Nephrol 37: 70-77, 1992
3. Hattori M, Kim Y, Steffes MV, Mauer SM: Structural functional relationships in type I mesangiocapillary glomerulonephritis. Kidney Int 43: 381-386, 1993
4. Alexopoulos E, Seron D, Hartley RB, Cameron JS: Lupus nephritis: Correlation of interstitial cells with glomerular function. Kidney Int 37: 100-109, 1990
5. Lane PH, Steffes MW, Fioretto P, Mauer SM: Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 43: 661-667, 1993
6. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62: 367-374, 1988
7. Harris KPG, Purkerson ML, Yates J, Klahr S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 15: 16-23, 1990
8. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33: 667-672, 1988
9. Gile RD, Cowley BD, Gattone VH, O'Donnell MP, Swan SK, Grantham JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26: 501-507, 1995
10. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91: 83-87, 1993
11. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21 ras-activated, AP-1-dependent pathway. Kidney Int 52: 1016-1027, 1997
12. Iimura O, Vrtovsnik F, Terzi F, Friedlander G: HMG CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture. Kidney Int 52: 962-972, 1997
13. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993
14. Barricos WH, Cortez SL, El-Dahr SS, Schnaper HW: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP2- cascade. Kidney Int 47: 1039-1047, 1995
15. Kita T, Brown MS, Goldstein JL: Feedback regulation of 3-hydroxy-3-methylglutaryl Coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 66: 1094-1100, 1980
16. Huarte J, Belin D, Vassalli J: Plasminogen activator in mouse and rat oocytes: Induction during meiotic maturation. Cell 43: 551-558, 1985
17. Loskutoff DJ, Schleef RR: Plasminogen activators and their inhibitors. Methods Enzymol 163: 293-302, 1988
18. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970
19. Casey P: Protein lipidation in cell signaling. Science 268: 221-225, 1995
20. Adamson P, Marshall CJ, Hall A, Tilbrook PA: Posttranslational modification of p21rho proteins. J Biol Chem 267: 20033-20038, 1992
21. Desnoyers L, Anant JS, Seabra MC: Geranylgeranylation of Rab proteins. Biochem Soc Trans 24: 699-703, 1996
22. Chardin P, Bocquet P, Madaule P, Popoff MR, Rubin EJ, Gill DM: The mammalian G protein RhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells. EMBO J 8: 1087-1092, 1989
23. Ridley AJ, Hall A: The small GTP-binding protein Rho regulates the assembly of focal adhesion and actin stress fibers in response to growth factor. Cell 70: 389-399, 1992
24. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P: Inhibition of human vascular smooth muscle cell proliferation by lovastatin: The role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 24: 766-772, 1994
25. Corsini A, Raiteri M, Soma MR, Fumagalli R, Paoletti R: Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 23: 173-180, 1991
26. Larsson O, Barrios C, Latham C, Ruiz J, Zetterberg A, Zickert P, Wejde J: Abolition of mevinolin-induced growth inhibition in human fibroblasts following transformation by simian virus 40, Cancer Res 49: 5605-5610, 1989
27. Corsini A, Maggi FM, Catapano AL: Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31: 9-27, 1995
28. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990
29. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO: Plasminogen activator expression in human advanced atherosclerotic lesions. Arterioscler Thromb Vasc Biol 15: 1444-1455, 1995
30. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J: Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vase Biol 15: 893-902, 1995
31. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Nat! Acad Sci USA 89: 6998-7002, 1992
32. Casey PJ, Solski PA, Der CJ, Buss JE: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86: 8323-8327, 1989
33. Mendola CE, Baker JM: Lovastatin blocks N-ras oncogene-induced neuronal differentiation. Cell Growth Differ 1: 499-502, 1990
34. Lengyel E, Stepp E, Gum R, Boyd D: Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem 270: 23007-23012, 1995
35. Takaishi K, Kikkuchi A, Kuroda S, Kotani K, Sasaki T, Takai Y: Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility. Mol Cell Biol 13: 72-79, 1993
36. Kishi K, Sasaki T, Kuroda S, Itoh T, Takai Y: Regulation of cytoplasmic division of Xenopus embryo by rho p21 and its inhibitory GDP/GDT exchange protein (rho GDI). J Cell Biol 120: 1187-1195, 1993
37. Fenton RG, Kung HF, Longo DL, Smith MR: Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol 117: 347-356, 1992
38. Bifulco M, Laezza C, Aloj SM, Garbi C: Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol 155: 340-348, 1993
39. Snyder RW, Lenburg ME, Seebaum AT, Grabel LB: Disruption of the cytoskeleton-extracellular matrix linkage promotes the accumulation of plasminogen activitors in F9 derived parietal endoderm. Differentiation 50: 153-162, 1992
40. Botteri FM, Ballmer-Hofer K, Rajput B, Nagamine Y: Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression. J Biol Chem 265: 13327-13334, 1990
41. Lee JS, von der Ahe D, Kiefer B, Nagamine Y: Cytoskeletal reorganisation and TAP differently modify AP-1 to induce the urokinase-type plasminogen activitor gene in LLC-PK1 cells. Nucleic Acids Res 21: 3365-3372, 1995
42. Irigoyen JP, Besser D, Nagamine Y: Cytoskeleton reorganisation induces the urokinase-type plasminogen activator gene via the ras/extracellular signal-regulated kinase (ERK) signaling pathway. J Biol Chem 272: 1904-1909, 1997